PE20010205A1 - Derivados 3-sustituido de 2-carboxiciclopropil glicina como agonistas de glutamato - Google Patents

Derivados 3-sustituido de 2-carboxiciclopropil glicina como agonistas de glutamato

Info

Publication number
PE20010205A1
PE20010205A1 PE2000000525A PE0005252000A PE20010205A1 PE 20010205 A1 PE20010205 A1 PE 20010205A1 PE 2000000525 A PE2000000525 A PE 2000000525A PE 0005252000 A PE0005252000 A PE 0005252000A PE 20010205 A1 PE20010205 A1 PE 20010205A1
Authority
PE
Peru
Prior art keywords
carboxyclopropyl
glycine
alkyl
lil
substituted derivatives
Prior art date
Application number
PE2000000525A
Other languages
English (en)
Inventor
Tercero Maria Concepcion Pedregal
Cano Ivan Collado
Garcia Maria Rosario Gonzalez
Llorente Alicia Marcos
De Uralde Garmendia Beatriz Lopezz
Melendo Ana Belen Bueno
Original Assignee
Lilly Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Sa filed Critical Lilly Sa
Publication of PE20010205A1 publication Critical patent/PE20010205A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A DERIVADOS 3-SUSTITUIDO DE 2-CARBOXICICLOPROPIL GLICINA DE FORMULA I, DONDE: R1 ES HALO-ALQUILO C1-C10, HALO-ALQUENILO C2-C10, (CH2)nY, SH, S(O)pR4, S(O)3H, NH2, NHR5, NR6R7, NHCOR8, NO2, CO2H, CONHR9, 1H-TETRAZO-5-LIL, 5-FENILTETRAZO-1-LIL, PO3H2; n ES 1-2, Y ES OH, CN, N3, OR3; R5, R6, R7, R8, R9 SON ALQUILO C1-C4, ARILO, ARIL-ALQUILO C1-C4, 1H-TETRAZO-5-LIL, CARBOXI-ALQUILO C1-C4, 1H-TETRAZO-5-LIL-ALQUILO C1-C4; p ES 0-3. SON COMPUESTOS PREFERIDOS (2SR, 1`SR, 2'SR, 3'SR)-2-[(3'(2''-HIDROXIETIL)-2'-CARBOXI)CICLOPROPIL]GLICINA, (2SR, 1RS, 2'RS, 3'RS)-2-[3'-MERCAPTOMETIL-2'-CARBOXICICLOPROPIL]GLICINA, (2S,1'S,2'R,3'R)-2-(3'-HIDROXIMETIL-2'-CARBOXICICLOPROPIL)GLICINA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION Y A COMPUESTOS INTERMEDIOS. LOS COMPUESTOS I SON AGONISTAS DE GLUTAMATO EN LOS RECEPTORES METABOTROPICOS Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE DESORDENES DEL SISTEMA NERVIOSO CENTRAL COMO ENFERMEDADES NEUROLOGICAS, NEURODEGENERATIVAS
PE2000000525A 1999-06-03 2000-05-31 Derivados 3-sustituido de 2-carboxiciclopropil glicina como agonistas de glutamato PE20010205A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99500090 1999-06-03

Publications (1)

Publication Number Publication Date
PE20010205A1 true PE20010205A1 (es) 2001-03-16

Family

ID=8242502

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000525A PE20010205A1 (es) 1999-06-03 2000-05-31 Derivados 3-sustituido de 2-carboxiciclopropil glicina como agonistas de glutamato

Country Status (6)

Country Link
US (1) US6498180B1 (es)
EP (1) EP1189873A1 (es)
AU (1) AU5073600A (es)
CO (1) CO5180545A1 (es)
PE (1) PE20010205A1 (es)
WO (1) WO2000075101A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2849025B1 (fr) * 2002-12-20 2005-10-14 Rhodia Chimie Sa Esters d'allyle substitue par un groupe difluoromethylene, leur procede de synthese et leur utilisation
US7125871B2 (en) * 2000-05-31 2006-10-24 Eli Lilly And Company Excitatory amino acid receptor modulators
US7081481B2 (en) * 2000-05-31 2006-07-25 Eli Lilly And Company Excitatory amino acid receptor modulators
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
CN101801930B (zh) * 2007-09-14 2013-01-30 奥梅-杨森制药有限公司 1,3-二取代的-4-苯基-1h-吡啶-2-酮
US9114138B2 (en) 2007-09-14 2015-08-25 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
JP5366269B2 (ja) 2007-09-14 2013-12-11 ジャンセン ファーマシューティカルズ， インコーポレイテッド． １，３−二置換４−（アリル−ｘ−フェニル）−１ｈ−ピリジン−２−オン
US8785486B2 (en) 2007-11-14 2014-07-22 Janssen Pharmaceuticals, Inc. Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
WO2010025890A1 (en) 2008-09-02 2010-03-11 Ortho-Mcneil-Janssen Pharmaceuticals, Inc 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MX2011011962A (es) 2009-05-12 2012-02-28 Janssen Pharmaceuticals Inc Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostericos positivos de receptores de glutamato metabotropico (mglur2).
SG10201402250TA (en) 2009-05-12 2014-07-30 Janssen Pharmaceuticals Inc 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
WO2012062750A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EP2643320B1 (en) 2010-11-08 2015-03-04 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
ES2552879T3 (es) 2010-11-08 2015-12-02 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
JP6416125B2 (ja) * 2013-02-04 2018-10-31 プレクストン・セラピューティクス・ソシエテ・アノニム ｍＧｌｕＲ３の正のアロステリックモジュレーター
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
EA201891617A3 (ru) 2014-01-21 2019-04-30 Янссен Фармацевтика Нв Комбинации, содержащие положительные аллостерические модуляторы или ортостерические агонисты метаботропного глутаматергического рецептора 2 подтипа, и их применение
HUE053734T2 (hu) 2014-01-21 2021-07-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait tartalmazó kombinációk és alkalmazásuk

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3481975B2 (ja) * 1992-09-08 2003-12-22 サントリー株式会社 （２ｓ，１’ｓ，２’ｒ）−２−（２−カルボキシ−３−置換オキシメチルシクロプロピル）グリシン及びその製造法
JPH08301825A (ja) 1995-03-07 1996-11-19 Suntory Ltd ３’−置換−（２−カルボキシシクロプロピル）グリシン
IT1276153B1 (it) 1995-11-17 1997-10-27 Roberto Pellicciari Derivati di glicina ad attivita' antagonista dei recettori metabotropi del glutammato
WO1998000391A1 (fr) 1996-06-28 1998-01-08 Nippon Chemiphar Co., Ltd. Derives de cyclopropylglycine et agoniste du recepteur du l-glutamate du type a regulation metabolique
ES2131463B1 (es) * 1997-04-08 2000-03-01 Lilly Sa Derivados de ciclopropilglicina con propiedades farmaceuticas.

Also Published As

Publication number Publication date
AU5073600A (en) 2000-12-28
EP1189873A1 (en) 2002-03-27
US6498180B1 (en) 2002-12-24
CO5180545A1 (es) 2002-07-30
WO2000075101A1 (en) 2000-12-14

Similar Documents

Publication Publication Date Title
PE20010205A1 (es) Derivados 3-sustituido de 2-carboxiciclopropil glicina como agonistas de glutamato
PE20080947A1 (es) Derivados de n-(amino-heteroaril)-1h-indol-2-carboxamidas como antagonistas de receptores de tipo trpv1
PE20040775A1 (es) DERIVADOS DE INDOL COMO AGONISTAS DE ADRENORECEPTORES ß2
CR7510A (es) DERIVADOS DE [1-4] DIAZEPINO[6,7,1-iJ)] QUINOLONA COMO AGENTES ANTIPSICOTICOS Y CONTRA LA OBESIDAD
PE20020911A1 (es) Derivados de indol como agonistas de 5ht2
CZ20032798A3 (cs) Nové pouzití slouceniny peptidové trídy pro lécbuallodynie nebo dalsích odlisných typu chronické nebo fantomové bolesti
CR6616A (es) Nuevos derivados de biarileter utiles como inhibidores de la recaptacion de monoaminas
BRPI0820112B8 (pt) derivados de isoxazol-piridina, seu uso e processos de preparação e medicamento
UY28144A1 (es) Agentes terapéuticos
CY1106645T1 (el) Παραγωγα 1,2,4 τριαμινοβενζολης χρησιμα για τη θεραπευτικη αντιμετωπιση διαταραχων του κεντρικου νευρικου συστηματος
EA200500174A1 (ru) Новые производные бензимидазола, полезные в качестве антипролиферативных агентов
UY28376A1 (es) Agentes terapéuticos
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
RU94030812A (ru) Производные фосфоноянтарной кислоты, способ их получения и содержащие эти соединения фармацевтические композиции
KR910000735A (ko) 융합된 2, 3-디하이드록시피라진 및 이의 제조방법
BR0314488A (pt) Composto, composição farmacêutica e métodos de tratamento
ES2069330T3 (es) Derivados de hidrazona, su preparacion y uso.
ES2291454T3 (es) Utilizacion de carbamatos para prevenir o tratar trastornos del movimiento.
AR053206A1 (es) Derivados de isoindoles, composiciones farmaceuticas que los contienen, sus utilizaciones terapeuticas como inhibidores de la actividad de la proteina chaperona hsp90 y su empleo en la preparacion de medicamentos para el tratamiento de diversos tipos de cancer.
ES2133324T3 (es) Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y metodos de uso.
EA199900161A1 (ru) Производные пиридазино [4,5-в]-хинолин-5-оксида, их получение и применение в качестве антагонистов глицина
BR0311593A (pt) Derivados de 1-sulfonil-4-aminoalcoxi indol como moduladores de receptor 5-ht6 para tratamento dos distúrbios de snc
UY28377A1 (es) Agentes terapeuticos
AR035750A1 (es) Uso de n- (piridinilamino) indoles para la preparacion de medicamentos para el tratamiento de enfermedades o trastornos desmielinizantes
PE20021016A1 (es) Conjugados de pregabalina-lactosa

Legal Events

Date Code Title Description
FC Refusal